Skip to main content
OpenTrials
Completed

NCT Number: NCT04725591

Diabeloop for Teens

An open-label, three-centers, controlled, randomized, and crossover study containing 14 days of baseline period with standard of care (SOC) therapy followed by two-sessions of 4-weeks home study phase with Diabeloop closed-loop (CL) system comparing the declaration of meals and the non-declaration of meals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Closed Loop Adolescents (12 to 17 Years Old) Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Age range

12 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospitals Leuven, Leuven, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Device-related inclusion criteria

  • age 12 - <18 years (i.e 17 years and 364 days) at time of screening
  • Type 1 diabetes Study-specific inclusion criteria
  • Subject has a clinical diagnosis of type 1 diabetes for at least 1 year as determined via medical records or source documentation by an individual qualified to make a medical diagnosis or confirmed C peptide negative.
  • An insulin pump user, or patient under Multiple Daily Injection (MDI), with or without CGM experience.
  • Subject having a Glycosylated hemoglobin (HbA1c) blood value > 8 % at time of screening visit-based on analysis from local laboratory within 3 months.
  • Living in an area covered by a GSM (Global System for Mobile Communications) network
  • Patient not isolated, does not live alone, or has a person living nearby who has a telephone and a key to his or her home
  • Patient willing to wear the system continuously throughout the study
  • Must be able to speak and be literate in French, in Dutch or in German
  • Having provided written assent & parents/guardian having provided written informed consent

Exclusion criteria

Device-related exclusion criteria

  • Patient receiving a total daily dose of insulin lower than 8 U
  • Patient having severe uncorrected problems of hearing and/or visual acuity
  • Patient unable to understand and perform all of the instructions provided by Diabeloop SA Study-specific exclusion criteria
  • Subject is unable to tolerate tape adhesive around the sensor or pump placements
  • Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
  • Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
  • Is being treated for hyperthyroidism at time of screening
  • Has diagnosis of adrenal insufficiency
  • Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the study
  • Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
  • Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
  • Currently abusing illicit drugs
  • Currently abusing marijuana
  • Currently abusing prescription drugs
  • Currently abusing alcohol
  • Subject is using pramlintide (Symlin), DDP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening
  • Subject has elective surgery planned that requires general anesthesia during the study
  • Has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
  • Plans to receive red blood cell transfusion or erythropoietin over study participation
  • Diagnosed with current eating disorder such as anorexia or bulimia
  • Diagnosed with chronic kidney disease that results in chronic anemia
  • Hematocrit that is below the normal reference range of lab used
  • Patient who has had a pancreatectomy or who has pancreatic malfunctions
  • Patient with pancreatic islet transplantation or pancreas transplantation
  • Patient on dialysis
  • Patient with impaired hepatic functions
  • Serum creatinine > 176 µmol/L
  • Any other physical or psychological disease, or medication likely to interfere with the conduct of the study and interpretation of the study results as judged by the investigator.
  • Pregnancy or breastfeeding
  • Untreated coeliac disease (2 x ULN local laboratory)
  • Untreated or unstable thyroid disease
  • Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any of the following during the 6 months prior to screening:
  • Medical assistance (i.e. Paramedics, Emergency Room or Hospitalization)
  • Coma
  • Seizures
  • Subject having severe diabetic ketoacidosis in the 6 months prior to screening visit
  • Impaired awareness of hypoglycemia (Gold Score > 4)

Treatment and study plan

Dexcom G6 Continuous Glucose Monitoring

Device

Collection of glucose data

MEDISAFE WITH External Insulin Pump

Device

Insulin delivery

Diabeloop Software (Model predictive control)

Device

Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.

Declaration of meals

Other

Patient inputs related to meals

No declaration of meals

Other

No patient inputs related to meals

Remote monitoring (Telemedicine)

Other

Remote follow up by care health providers team

Primary outcomes

  1. The primary outcome is the time spent of the glucose level in the widened target range 3.9-10.0 mmol/L over the 2 last weeks of each cross-over period, as recorded by continuous subcutaneous glucose monitoring (CGM).

    Time frame: 2 weeks

    Measurement of glucose by CGM

Secondary outcomes

  1. Incidence of severe hypoglycemia as defined by the ISPAD guidelines:

    Time frame: 10 weeks

    • Number of severe hypoglycemic episodes needing a third-party intervention
    • Number of severe hypoglycemic episodes with loss of consciousness
    • Number of hospitalizations because of a severe hypoglycemia episode
    • Number of hypoglycemic episodes, defined by any crossing of the threshold of 3.33 mmol/L, 3.9 mmol/L, 3.0mmol/L and < 2.8 mmol/L measured continuous glucose monitoring.

  2. • Number of severe hyperglycemia episodes with beginning and end episode as measured by the Dexcom G6 CGM

    Time frame: 10 weeks

    o >19.4 mmol/L or significant ketosis (plasmatic ketones > 3 mmol/L) as defined by the ADA.

  3. • Incidence of severe hyperglycemia

    Time frame: 10 weeks

    o Number of events requiring an emergency room visit or hospitalizations because of ketoacidosis (i.e. incidence of DKA)

  4. • Percent of CGM time with glucose < 3.9 mmol/L

    Time frame: 10 weeks

    Measurement of glucose by CGM

  5. • Percent of CGM time in glucose range 3.9-10.0 mmol/L

    Time frame: 10 weeks

    Measurement of glucose by CGM

  6. • Mean CGM glucose

    Time frame: 10 weeks

    Measurement of glucose by CGM

  7. • Percentage of sensor time in glucose level measured by the Dexcom G6 CGM, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am

    Time frame: 24 hours

    • < 2.8 mmol/L
    • < 3.0 mmol/L
    • < 3.3 mmol/L
    • < 3.9 mmol/L

  8. • Number of hypoglycemic episodes with beginning and end of episode as measured by the Dexcom G6 CGM for at least 15 minutes

    Time frame: 10 weeks

    • < 3.9 mmol/L
    • < 3.0 mmol/L
    • ≤ 2.8 mmol/L

  9. • Percentage of sensor time in glucose level measured by the Dexcom G6 CGM, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am

    Time frame: 24 hours

    • > 10.0 mmol/L
    • > 13.9 mmol/L
    • > 16.7 mmol/L
    • > 19.4 mmol/L

  10. • Number of severe hyperglycemia episodes with beginning and end of episode as measured by the Dexcom G6 CGM

    Time frame: 10 weeks

    o > 19.4 mmol/L

  11. • Number of serious adverse events, serious adverse device events, unanticipated adverse device effects

    Time frame: 10 weeks

  12. • Risk of hypoglycemia and hyperglycemia (LBGI/HBGI)

    Time frame: 10 weeks

    Measurement of glucose by CGM

  13. • Percentage of time spent in the 3.9-10.0 mmol/L target range, for the last 2 weeks of each cross-over session during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am

    Time frame: 2 weeks

    Measurement of glucose by CGM

  14. • Percentage of sensor time in glucose range 2.8 - 3.9 mmol/L, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am

    Time frame: 24 hours

    Measurement of glucose by CGM

  15. • Percentage of sensor time in glucose range 3.9 - 7.8 mmol/L, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am

    Time frame: 24 hours

    Measurement of glucose by CGM

  16. • Percentage of sensor time in glucose range 3.9 - 10.0 mmol/L, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am

    Time frame: 24 hours

    Measurement of glucose by CGM

  17. • Evolution of HbA1c calculated from CGM data

    Time frame: 10 weeks

    Measurement of glucose by CGM

  18. • Average CGM glucose level during the entire period

    Time frame: 10 weeks

    Measurement of glucose by CGM

  19. • Average fasting CGM glucose level at 6:00 am

    Time frame: 10 weeks

    Measurement of glucose by CGM

  20. • Variability of the CGM glucose level

    Time frame: 10 weeks

    • the glycemic variation coefficient (CV) intra patient: CV < 36% CV ≥ 36%
    • Standard deviation (SD)

  21. • Average dose of insulin used & its daily evolution during the entire study duration

    Time frame: 10 weeks

  22. • Number of technical incidents leading to the interruption of the closed loop

    Time frame: 8 weeks

  23. • Evolution over time of the DBL system's performance on a day-to-day and determination of the optimization delay of glycemic control

    Time frame: 8 weeks

    Measurement of glucose by CGM

  24. • Evolution of the weekly average number of CHO intake (for patient with closed-loop)

    Time frame: 8 weeks

  25. • Percentage of time spent in closed loop mode (i.e. DBL System with loop mode operating)

    Time frame: 8 weeks

  26. • Percentage of time spent in operating mode for the Dexcom G6 CGM

    Time frame: 10 weeks

  27. • Scoring of a questionnaire to evaluate the acceptance

    Time frame: 10 weeks

    o Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a 12-item measure that enables self-reporting of the satisfaction about their current treatment. Scale is from 6 (very satisfied) to 0 (very dissatisfied).

  28. • Scoring of a questionnaire to evaluate the acceptance

    Time frame: 10 weeks

    o Diabetes Technology Questionnaire (DTQ) aims to evaluate the impact of the closed-loop system use and diabetes specific quality of life measures in the study participants and their families, as well as satisfaction of system, as compared to conventional treatment options. The subject will answer by choosing from 5 suggestions : Strongly agree - Agree - Neither agree nor disagree - Disagree - Strongly disagree.

Sponsors and collaborators

Lead sponsor

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

Other

Registry information

Official study title

An Open-label, Multicenter, Randomized, Crossover Study, to Assess 4 Weeks Outpatient, the Clinical Efficacy of the Diabeloop Closed-loop Glucose Control Without the Declaration of Meals Compared with the Diabeloop Closed-loop Glucose Control with the Declaration of Meals, in Adolescent Patients with Type 1 Diabetes Poorly Controlled.

Acronym: DBL4T

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jan 26, 2021
Registry last updated
Sep 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.